Search Results - "Mould, D.R"

Phase 1b Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy (CRT)-Induced Oral Mucositis (OM) in Patients (pts) With Oral Cavity or Oropharyngeal Carcinoma (OCC) by Anderson, C.M, Allen, B.G, Sun, W, Agarwala, S.S, Lee, C.M, Venigalla, M.L, Greenberg, L, Adkins, D, Chen, Y, Zhen, W, Mould, D.R, Holmlund, J, Brill, J, Sonis, S.T, Buatti, J

Get full text

367 Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies by Zhou, X, Nemunaitis, J, Pant, S, Bauer, T.M, Patel, M, Sarantopoulos, J, Lockhart, A.C, Goodman, D, Zhang, B, Ullmann, C. Dansky, Mould, D.R, Venkatakrishnan, K

Get full text

9428 POSTER Pharmacokinetics and Pharmacodynamics of Liposomal Mifamurtide in Patients With Osteosarcoma by Venkatakrishnan, K, Meyers, P, Mould, D.R, Green, B, Synold, T.W, Oliva, C, Anderson, P

Get full text

26301 Pharmacokinetic analyses show limited systemic exposure with topical glycopyrronium tosylate by Pariser, D.M., Lain, E.L., Mamelok, R., Aurora, B., Mould, D.R.

Get full text

BRENTUXIMAB VEDOTIN POPULATION PHARMACOKINETIC (POPPK) MODELLING IN ADULT AND PAEDIATRIC PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) HEMATOLOGIC MALIGNANCIES by Suri, A., Mould, D.R., Song, G., Kinley, J., Venkatakrishnan, K.

Get full text

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II by Nijenhuis, C.M., Lucas, L., Rosing, H., Huitema, A.D.R., Mergui-Roelvink, M., Jamieson, G. C., Fox, J.A., Mould, D.R., Schellens, J.H.M., Beijnen, J.H.

“…Summary Background Vosaroxin is a first-in-class anticancer quinolone derivative that is being investigated for patients with relapsed or refractory acute…”
Get full text

Implications of including and excluding correlation of random effects in hierarchical mixed effects pharmacokinetic (PK) models by Gobburu, J.V., Mould, D.R., Holford, N.H.

“…Clinical Pharmacology & Therapeutics (2003) 73, P25–P25; doi:…”
Get full text

P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis by Scholz, C., Wyant, T., Leach, T., Sankoh, S., Mould, D.R., Patella, M., Parikh, A., Fox, I., von Moltke, L.

Get full text

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience by O'Connor, Owen A., Hamlin, P.A., Gerecitano, J., Portlock, C.S, Noy, A., Moskowitz, C., Straus, D.J., Sarasohn, D., Dumetrescu, O., Pappanicolou, J., Neylon, E., Zelenetz, A.D., Saunders, M.E., Mould, D.R., Fleischer, M., Sirotnak, F., Horwitz, S.M.

“…T-cell lymphomas (TCL) represent a diverse and heterogeneous group of diseases. The prognosis of patients with TCL is generally much worse than for patients…”
Get full text

A population PK (PPK) and logistic regression (LR) analysis of lotrafiban (L) in patients by Mould, D.R., Aluri, J.B., Chapelsky, M.C., Granett, J.G., Samuels, R.

“…Clinical Pharmacology & Therapeutics (1999) 65, 179–179; doi:…”
Get full text